Neurocrine Biosciences (NBIX) Income from Continuing Operations (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Income from Continuing Operations of 197900000.0 for Q1 2026, up 28.76% on a QoQ basis from 153700000.0 in Q4 2025, and up 2405.06% year-over-year from 7900000.0 in Q1 2025.
Neurocrine Biosciences (NBIX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 197900000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 2405.06% year-over-year to 197900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 668600000.0 (up 118.64% YoY) and the FY2025 annual result came in at 478600000.0, up 40.23% from the prior year.
- Income from Continuing Operations was 197900000.0 for Q1 2026 at Neurocrine Biosciences, up from 153700000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 209500000.0 in Q3 2025 and bottomed at 76600000.0 in Q1 2023.
- A 5-year average of 83647058.82 and a median of 89000000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 651.08% — and 2026, when it soared 2405.06%.
- Neurocrine Biosciences' Income from Continuing Operations stood at 89000000.0 in 2022, then soared by 65.96% to 147700000.0 in 2023, then plunged by 30.2% to 103100000.0 in 2024, then jumped by 49.08% to 153700000.0 in 2025, then advanced by 28.76% to 197900000.0 in 2026.
- Business Quant data shows NBIX's Income from Continuing Operations at 197900000.0 in Q1 2026, 153700000.0 in Q4 2025, and 209500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.90 Mn |
| Dec 31, 2025 | 153.70 Mn |
| Sep 30, 2025 | 209.50 Mn |
| Jun 30, 2025 | 107.50 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 103.10 Mn |
| Sep 30, 2024 | 129.80 Mn |
| Jun 30, 2024 | 65.00 Mn |
| Mar 31, 2024 | 43.40 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Sep 30, 2023 | 83.10 Mn |
| Jun 30, 2023 | 95.50 Mn |
| Mar 31, 2023 | -76.60 Mn |
| Dec 31, 2022 | 89.00 Mn |
| Sep 30, 2022 | 68.50 Mn |
| Jun 30, 2022 | -16.90 Mn |
| Mar 31, 2022 | 13.90 Mn |
| Dec 31, 2021 | -7.30 Mn |
| Sep 30, 2021 | 22.50 Mn |
| Jun 30, 2021 | 42.30 Mn |